Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
83,443,197
-
Share change
-
-256,221
-
Total reported value
-
$4,415,758,766
-
Put/Call ratio
-
83%
-
Price per share
-
$52.92
-
Number of holders
-
281
-
Value change
-
-$3,028,583
-
Number of buys
-
130
-
Number of sells
-
124
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2022
As of 31 Dec 2022,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
281 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
83,443,197 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, WASATCH ADVISORS INC, Bellevue Group AG, ALLIANCEBERNSTEIN L.P., STATE STREET CORP, FRANKLIN RESOURCES INC, and Invesco Ltd..
This page lists
281
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.